Cigna's Evernorth division is launching a $100 million artificial intelligence program focused on specialty drugs. The initiative will initially be implemented at Accredo, Evernorth's subsidiary that handles expensive and complex medications, aiming to leverage AI for improved management and outcomes of specialty drug therapies. Evernorth is the healthcare services business arm of Cigna.

Shares of Fidelity National Information Services Inc. (FIS) rose 4.94% to $40.80 on Wednesday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the stock's fourth consecutive day of gains.

Bank OZK (OZK) has announced an increase in its quarterly cash dividend to 48 cents per share, marking its sixty-fourth consecutive quarterly dividend raise. The bank boasts a GF Score™ of 80/100, indicating strong potential for long-term returns, and a P/E ratio of 8.59, suggesting it may be undervalued. While its financial strength is rated as moderate, the consistent dividend growth and favorable GF Score™ point to a solid position for future growth.

Oscar Health CEO Mark T Bertolini sold approximately $35.7 million worth of company stock through multiple transactions on June 29 and June 30, 2026. These sales, conducted to cover tax withholding obligations from vested performance stock units, involved 1,238,996 shares at weighted average prices between $28.35 and $30.08. Following these transactions, Bertolini retains direct ownership of 7,751,570 shares, while the company's stock has shown significant recent growth and positive analyst upgrades.

Mark Hancock, an affiliate of PACS, reported the sale of 500,000 shares of PACS common stock in June 2026 through five separate transactions. These sales generated aggregate proceeds of $18,875,341.54. The filing, a Form 144, serves as a regulatory notice of proposed or recent affiliate sales and does not specify the intended use of proceeds or details regarding a trading plan.

A Delta Air Lines passenger experienced a flight rescheduling and seat downgrade from Paris to Atlanta, receiving only 5,000 miles as a "goodwill gesture." This incident sparked a discussion on Reddit, with many pointing out that under strict EU Air Passenger Rights (EU 261), the passengers could be owed significantly more, potentially 600 EUR each plus 75% of the original fare for the downgrade. Aviation law expert Anton Radchenko confirmed that the flight change and early departure qualify as a cancellation under EU law, which offers far greater protection than U.S. DOT regulations for similar flight changes.

Q2 Holdings (QTWO) has been added to the Russell 2000 Defensive and Growth-Defensive Indexes, signaling its potential as a defensive growth stock within the small-cap market. This inclusion is linked to the company's digital banking platform and its new AI-enabled Q2 Assistant, which is attracting investor interest as financial software embraces AI. While index inclusion and AI momentum are positive, ongoing consolidation among Q2's client base of mid-sized banks and credit unions could pose a challenge.

PIMCO Corporate & Income Opportunity Fund (PTY) has declared a monthly dividend of $0.1188 per share, offering an attractive forward yield of 11.78%. Despite this, the fund has a GF Score™ of 49/100, with low ratings for financial strength and profitability. While its P/E ratio of 9.23x suggests potential undervaluation, investors are advised to consider the underlying financial metrics and risks.

Shares of Q2 Holdings, RingCentral, and Doximity saw significant jumps after Guggenheim analyst John DiFucci upgraded Salesforce and ServiceNow to Buy, citing AI-disruption fears having pushed valuations too low. This "valuation call from a skeptic" signaled that the "SaaSpocalypse" repricing had overshot, inviting bargain-hunting across the SaaS sector. Oracle's rise due to a new AI product and oversold conditions also contributed to the overall market recovery.

A director at Pharvaris NV (PHVS), Schikan Johannes Gerardus Christiaan Petrus, sold 37,600 shares of the company on June 30, 2026, reducing his holdings to 315,167 shares. This transaction is part of a pattern where the insider has sold a total of 80,000 shares over the past year with no purchases. The company, focused on rare disease therapies, saw its shares trading at $35.41 on the day of the sale, giving it a market capitalization of $2,367.875 million.